Thrivent Financial for Lutherans’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-73,399
Closed -$321K 2611
2026
Q1
$321K Sell
73,399
-2,161
-3% -$10.2K ﹤0.01% 2359
2025
Q4
$382K Sell
75,560
-3,374
-4% -$15.7K ﹤0.01% 2344
2025
Q3
$274K Buy
78,934
+3,495
+5% +$13.1K ﹤0.01% 2253
2025
Q2
$256K Sell
75,439
-1,199
-2% -$4K ﹤0.01% 2342
2025
Q1
$307K Sell
76,638
-4,009
-5% -$20.8K ﹤0.01% 2222
2024
Q4
$523K Sell
80,647
-3,001
-4% -$17.9K ﹤0.01% 2238
2024
Q3
$463K Buy
83,648
+4,096
+5% +$23.2K ﹤0.01% 2273
2024
Q2
$444K Sell
79,552
-6,290
-7% -$37.8K ﹤0.01% 2267
2024
Q1
$576K Sell
85,842
-2,329
-3% -$18.4K ﹤0.01% 2178
2023
Q4
$804K Sell
88,171
-2,880
-3% -$18.1K ﹤0.01% 1973
2023
Q3
$503K Buy
91,051
+14,479
+19% +$116K ﹤0.01% 2130
2023
Q2
$654K Buy
+76,572
New +$687K ﹤0.01% 2064

Other funds holding CTKB

Thrivent Financial for Lutherans's CTKB Position: Q2 2026 in Review

Thrivent Financial for Lutherans sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 73,399 shares — an estimated $321K sold.

Thrivent Financial for Lutherans first reported a position in CTKB in Q2 2023 and held it in 12 quarters. The position peaked at $804K in Q4 2023. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Thrivent Financial for Lutherans reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 73,399 Cytek Biosciences shares in Q2 2026, an estimated $321K.
  • Thrivent Financial for Lutherans first reported a position in Cytek Biosciences in Q2 2023 and held it in 12 quarters.
  • Thrivent Financial for Lutherans's Cytek Biosciences position peaked at $804K in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.